MedTrace Logo

Evaluation of HRQoL in Adult With Immune Thrombocytopenia in China

NCT03324087 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2017-10-27

No results posted yet for this study

Summary

Immune thrombocytopenia (ITP) is a heterogeneous disorder with variable clinical symptomsHealth related quality of life (HRQoL) could be considered in ITP, as in numerous chronic diseases, as a method to provide information about the effects of medical interventions. Symptoms of ITP, such as spontaneous bruising, menorrhagia, mucosal bleeding and prolonged bleeding with injury, may significantly affect HRQoL in ITP subjects. Treatments for chronic ITP can also be associated with substantial side effects. Restoring and/or maintaining quality of life should be an important goal of treatment. We conducted a real-world multicenter study using SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.

Conditions

Interventions

DIAGNOSTIC_TEST

HRQoL

use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University (Qingdao)

    collaborator OTHER

  • Jining Medical University

    collaborator OTHER

  • Liaocheng People's Hospital

    collaborator OTHER

  • Yantai Yuhuangding Hospital

    collaborator OTHER

  • Binzhou Medical University

    collaborator OTHER

  • Weifang People's Hospital

    collaborator OTHER

  • Linyi People's Hospital

    collaborator OTHER

  • Shengli Oilfield Hospital

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Ming Hou · Qilu Hospital, Shandong University

Eligibility

Min Age
14 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03324087 on ClinicalTrials.gov